Brief: Vigil Neuroscience Reports Q1 2023 Financial Results And Provides Business Update

Vigil Neuroscience

10/05/2023 13:32

May 10 (Reuters) - Vigil Neuroscience Inc  VIGL.O :
    * VIGIL NEUROSCIENCE REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
    * PARTIAL CLINICAL HOLD LIFTED BY FDA ON VGL101
    * INTERIM DATA FROM IGNITE PHASE 2 CLINICAL TRIAL OF VGL101
IN
PATIENTS WITH ALSP EXPECTED IN Q4 OF 2023
    * SMALL MOLECULE TREM2 AGONIST IND SUBMISSION AND INITIATION
OF
PHASE 1 CLINICAL TRIAL PLANNED FOR Q4 OF 2023
    * ON TRACK TO REPORT FULL DATA ANALYSIS FROM PHASE 1 HEALTHY
VOLUNTEER TRIAL OF VGL101 IN SECOND HALF OF 2023
    * EXPECTS ITS CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES TO
FUND ITS OPERATIONAL PLANS INTO THE FIRST QUARTER OF 2025
    * QTRLY LOSS PER SHARE $0.51
    * Q1 EARNINGS PER SHARE VIEW $-0.53, REVENUE VIEW $0.00 --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXbt6mDs 
Further company coverage:  VIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))